New Bladder-Sparing cocktail shows promise for tough cancer
NCT ID NCT02621151
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 23 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help control muscle-invasive bladder cancer while allowing patients to keep their bladder. It involves 60 adults who are not candidates for or choose not to have bladder removal surgery. The main goal is to see how many remain cancer-free in the bladder after two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE UROTHELIAL CANCER OF THE BLADDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering
New York, New York, 10065, United States
-
NYU Perlmutter Cancer Center
New York, New York, 10016, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599-7305, United States
Conditions
Explore the condition pages connected to this study.